Immunological efficacy of lactic acid bacteria for COVID-19

Immunological efficacy of lactic acid bacteria for COVID-19: an open-label trial - COVID-19/lactic acid bacteria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040479

Enrollment

Registered

2020-05-22

Start date

2020-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Using the lactic acid bacteria suitability assay, the best- and worst-matched species are selected for each subject from the following three species of lactic acid bacteria: Lactobacillus plantarum,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy volunteers

Exclusion criteria

Exclusion criteria: 1) Current infectious, inflammatory, or immune-related diseases 2) Pregnant female

Design outcomes

Primary

Measure	Time frame
Plasma cytokine levels after the administration of lactic acid bacteria for 7 days .	—

Secondary

Measure	Time frame
Hematology and blood biochemistry after the administration of lactic acid bacteria for 7 days .	—

Countries

Japan

Contacts

Public ContactTomoka Ebisui

Takanawa Clinic Administration Department

jimukyoku@takanawa-clinic.com03-6433-3165

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026